- Trial Phase
- Approved (Phase 3 for pipeline expansion)
- Time to Market
- Already FDA-approved and commercialized (December 2021 for gMG). Pipeline expansion into autoimmune myositis is in regulatory submission phase following positive Phase 3 data.
- Why 4/10
- Efgartigimod is already FDA-approved and generating >$1.5B in quarterly sales, so there is no single make-or-break binary catalyst. The next dated catalyst would be a regulatory submission for autoimmune myositis (following the positive Phase 3 ALKIVIA readout on Aug 17, 2026), but no PDUFA date has been set. Per rubric, an approved commercial drug with no pending regulatory decision scores 3-5 — this drug is central to argenx's value but commercial ramp is not a binary event.
Watch for argenx's regulatory filing for efgartigimod in autoimmune myositis following the positive Phase 3 ALKIVIA readout (Aug 17, 2026) — that submission will unlock a PDUFA catalyst. Also track Vyvgart quarterly sales growth trajectory (60% YoY) as the key driver of earnings beats and estimate revisions.
Price Chart
Executive Summary
Efgartigimod alfa (Vyvgart / Vyvgart Hytrulo) is argenx's first-in-class FcRn blocker approved for generalized myasthenia gravis and already generating over $1.5B in quarterly sales with 60% year-over-year growth. The drug is argenx's core commercial asset and the company's only marketed product, but it is already approved — there is no single binary catalyst ahead. The positive Phase 3 ALKIVIA readout in autoimmune myositis (Aug 17, 2026) opens pipeline expansion optionality, and the analyst consensus is strongly bullish (23 Buy/Strong Buy) with a ~13% implied upside to the mean price target. However, competition in the FcRn space is growing (UCB's Rystiggo, J&J's nipocalimab), some institutional funds trimmed in Q2, and the stock trades near its 52-week high. For an approved, revenue-generating drug, the risk/reward leans bullish on commercial momentum but lacks a near-term binary event.
How It Works
Efgartigimod is a 'FcRn blocker.' Normally, a recycling receptor (FcRn) keeps immunoglobulin G (IgG) antibodies — including the harmful autoantibodies that drive autoimmune disease — circulating in the bloodstream by rescuing them from breakdown. Efgartigimod binds and blocks FcRn, causing those autoantibodies to be degraded instead of recycled, reducing their levels by roughly 60-75%. This lowers the autoimmune attack without broadly suppressing the entire immune system like older treatments. Think of it as a targeted molecular 'antibody vacuum cleaner' that selectively clears the bad antibodies while leaving other immune functions relatively intact.
Trial Status
Efgartigimod is FDA-approved for generalized myasthenia gravis. Key pipeline readouts: Phase 3 ALKIVIA trial in autoimmune myositis met endpoints (positive topline Aug 17, 2026); Phase 3 in primary ITP completed; Phase 2 in Sjögren's completed; Phase 3 trials in thyroid eye disease and bullous pemphigoid were terminated.
The Two-Sided Case
Upcoming Catalysts
- Regulatory filing submission for efgartigimod in autoimmune myositis (pending, based on positive ALKIVIA Phase 3 data)
- Potential FDA/EMA filings for immune thrombocytopenia (ITP) data
- Q3 2026 earnings report (late October 2026) with updated sales trajectory
- Completion of Forte Biosciences acquisition (expected Q3 2026)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
argenx SE Press Release ARGX ·Originating report